Ποια είναι η τιμή για AIM Vaccine Co., Ltd. (6660)

Η τιμή για AIM Vaccine Co., Ltd. (6660) είναι $0.23346537

Ποια είναι η κεφαλαιοποίηση αγοράς για AIM Vaccine Co., Ltd. (6660)

Η κεφαλαιοποίηση αγοράς για AIM Vaccine Co., Ltd. (6660) είναι $285.87M

AIM Vaccine Co., Ltd. (6660) Λειτουργικό Περιθώριο

Operating within the People's Republic of China, AIM Vaccine Co., Ltd. specializes in the entire lifecycle of human vaccine products, encompassing their discovery, production, and market introduction. Among its current developments, the company is advancing Bivalent Delta-Omicron BA.5 mRNA and Monovalent Omicron BA.5 mRNA vaccine candidates for COVID-19, both currently undergoing Phase III clinical trials. Its comprehensive portfolio also features vaccines targeting a range of other conditions, such as an EV71-CA16 Bivalent vaccine for Hand, Foot, and Mouth Disease (HFMD), and both Conjugate and Polysaccharide versions for pneumococcal disease. Further offerings include a Hexavalent group B Streptococcus Polysaccharide Conjugate Vaccine, various Diphtheria, Tetanus, and Pertussis (DTP) formulations (including DTP combined with Haemophilus Influenzae type B, acellular pertussis, and absorbed tetanus), a Haemophilus Influenzae Type B (Hib) vaccine, and both traditional freeze-dried and innovative mRNA human rabies vaccines. Beyond these, AIM Vaccine is actively developing several other vaccines, including 2- and 3-valent Human Papillomavirus (HPV) vaccines, a Tetravalent Meningococcal Conjugate vaccine, a Tetravalent Influenza vaccine, mRNA-based vaccines for Shingles/Herpes Zoster and Respiratory Syncytial Virus (RSV), a live attenuated parotitis vaccine, and an ACYW135 meningococcal polysaccharide vaccine. Established in 2011 and headquartered in Beijing, PRC, the company adopted its current name, AIM Vaccine Co., Ltd., in September 2020, having previously operated as Beijing AIM Biological Vaccine Technology Group Co., Ltd.

Έτος	Λειτουργικό Περιθώριο	Αλλαγή
Δεν υπάρχουν αρκετά δεδομένα για τις παρεχόμενες ημερομηνίες.

Έτος

Λειτουργικό Περιθώριο

Αλλαγή

Δεν υπάρχουν αρκετά δεδομένα για τις παρεχόμενες ημερομηνίες.

Εταιρεία	Λειτουργικό Περιθώριο	Διαφορά Λειτουργικού Περιθωρίου	Χώρα
Vertex Pharmaceuticals Incorporated VRTX.US	38.59%	-	US
Argenx SE ARGX.US	28.81%	-	NL
Moderna, Inc. MRNA.US	-149.01%	-	US
CSL Limited CSL.AX	25.57%	-	AU
Lonza Group AG LONN.SW	0.00%	-	CH

Εταιρεία

Λειτουργικό Περιθώριο

Διαφορά Λειτουργικού Περιθωρίου

Χώρα